| http://dbpedia.org/ontology/abstract
|
The β3 (beta 3) adrenergic receptor agonis … The β3 (beta 3) adrenergic receptor agonist or β3-adrenoceptor agonist, also known as β3-AR agonist, are a class of medicine that bind selectively to β3-adrenergic receptors. β3-AR agonists for the treatment of obesity and type 2 diabetes have been in developmental stages within many large pharmaceutical companies since the early 1990s without successfully delivering an anti-obesity product to the market. More recently pharmaceutical companies have developed selective β3-AR agonists targeted at urinary inconsistencies and in 2012 Mirabegron (trade name Myrbetriq and Betmiga) was the first β3-AR agonist to be approved in the United States and Europe for the treatment of overactive bladder (OAB) syndrome.ment of overactive bladder (OAB) syndrome.
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Mirabegron.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
58646004
|
| http://dbpedia.org/ontology/wikiPageLength
|
21789
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1112387230
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Diabetes_mellitus_type_2 +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/File:Vibegron.svg +
, http://dbpedia.org/resource/File:Phenylethanolamine.png +
, http://dbpedia.org/resource/Adenylyl_cyclase +
, http://dbpedia.org/resource/File:Solabegron.svg +
, http://dbpedia.org/resource/File:IUPAC_-_N-%284-%282-%28%282-hydroxy-2-%28pyridin-3-yl%29ethyl%29amino%29ethyl%29phenyl%29-4-%284-%284-%28trifluoromethyl%29phenyl%29thiazol-2-yl%29benzenesulfonamide.jpg +
, http://dbpedia.org/resource/Mirabegron +
, http://dbpedia.org/resource/File:Mirabegron.svg +
, http://dbpedia.org/resource/G_protein-coupled_receptor +
, http://dbpedia.org/resource/File:IUPAC_-_2-amino-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29-5%2C6-dihydro-4H-cyclopenta-%28d%29-thiazole-4-carboxamide.jpg +
, http://dbpedia.org/resource/European_Commission +
, http://dbpedia.org/resource/File:IUPAC_-_3-%283-%28%282R%29-2-%28%282-%283-chlorophenyl%29-2-hydroxyethyl%29amino%29propyl%29-1H-indol-7-yl%29propanoic_acid.jpg +
, http://dbpedia.org/resource/Category:Beta3-adrenergic_agonists +
, http://dbpedia.org/resource/GlaxoSmithKline +
, http://dbpedia.org/resource/Urinary_bladder +
, http://dbpedia.org/resource/Inotrope +
, http://dbpedia.org/resource/Smooth_muscle +
, http://dbpedia.org/resource/File:IUPAC_-_2-%282-aminothiazol-4-yl%29-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29butanamide.jpg +
, http://dbpedia.org/resource/File:IUPAC_-_2-%282-aminothiazol-4-yl%29-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29propanamide.jpg +
, http://dbpedia.org/resource/File:Basic_structure_for_beta_3_adrenergic_receptor_agonist.jpg +
, http://dbpedia.org/resource/File:IUPAC_-_2-%282-aminothiazol-4-yl%29-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29acetamide.jpg +
, http://dbpedia.org/resource/Ephedrine +
, http://dbpedia.org/resource/Astellas_Pharma +
, http://dbpedia.org/resource/Detrusor_muscle +
, http://dbpedia.org/resource/Vibegron +
, http://dbpedia.org/resource/Irritable_bowel_syndrome +
, http://dbpedia.org/resource/Beta-3_adrenergic_receptor +
, http://dbpedia.org/resource/Lower_urinary_tract_symptoms +
, http://dbpedia.org/resource/Nebivolol +
, http://dbpedia.org/resource/Merck_&_Co. +
, http://dbpedia.org/resource/Thermogenesis +
, http://dbpedia.org/resource/Urination +
, http://dbpedia.org/resource/Stereochemistry +
, http://dbpedia.org/resource/Skeletal_muscle +
, http://dbpedia.org/resource/Agonist +
, http://dbpedia.org/resource/Beta-adrenergic_agonist +
, http://dbpedia.org/resource/Ligand +
, http://dbpedia.org/resource/Obesity +
, http://dbpedia.org/resource/Enzyme +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Cyclic_adenosine_monophosphate +
, http://dbpedia.org/resource/Heart_failure +
, http://dbpedia.org/resource/Beta2-adrenergic_agonist +
, http://dbpedia.org/resource/Intracellular +
, http://dbpedia.org/resource/Gi_alpha_subunit +
, http://dbpedia.org/resource/Gs_alpha_subunit +
, http://dbpedia.org/resource/Solabegron +
, http://dbpedia.org/resource/Beta-1_adrenergic_receptor +
, http://dbpedia.org/resource/Beta-2_adrenergic_receptor +
, http://dbpedia.org/resource/Extracellular +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Short_description +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Beta3-adrenergic_agonists +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Beta3-adrenergic_agonist?oldid=1112387230&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/IUPAC_-_2-%282-aminothiazol-4-yl%29-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29propanamide.jpg +
, http://commons.wikimedia.org/wiki/Special:FilePath/IUPAC_-_2-amino-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29-5%2C6-dihydro-4H-cyclopenta-%28d%29-thiazole-4-carboxamide.jpg +
, http://commons.wikimedia.org/wiki/Special:FilePath/IUPAC_-_3-%283-%28%282R%29-2-%28%282-%283-chlorophenyl%29-2-hydroxyethyl%29amino%29propyl%29-1H-indol-7-yl%29propanoic_acid.jpg +
, http://commons.wikimedia.org/wiki/Special:FilePath/IUPAC_-_N-%284-%282-%28%282-hydroxy-2-%28pyridin-3-yl%29ethyl%29amino%29ethyl%29phenyl%29-4-%284-%284-%28trifluoromethyl%29phenyl%29thiazol-2-yl%29benzenesulfonamide.jpg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Mirabegron.svg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Basic_structure_for_beta_3_adrenergic_receptor_agonist.jpg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Vibegron.svg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Solabegron.svg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Phenylethanolamine.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/IUPAC_-_2-%282-aminothiazol-4-yl%29-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29acetamide.jpg +
, http://commons.wikimedia.org/wiki/Special:FilePath/IUPAC_-_2-%282-aminothiazol-4-yl%29-N-%284-%28%28%282S%2C5R%29-5-%28hydroxy%28phenyl%29methyl%29pyrrolidin-2-yl%29methyl%29phenyl%29butanamide.jpg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Beta3-adrenergic_agonist +
|
| owl:sameAs |
http://dbpedia.org/resource/Beta3-adrenergic_agonist +
, https://global.dbpedia.org/id/6bNxv +
, http://www.wikidata.org/entity/Q56883537 +
|
| rdfs:comment |
The β3 (beta 3) adrenergic receptor agonis … The β3 (beta 3) adrenergic receptor agonist or β3-adrenoceptor agonist, also known as β3-AR agonist, are a class of medicine that bind selectively to β3-adrenergic receptors. β3-AR agonists for the treatment of obesity and type 2 diabetes have been in developmental stages within many large pharmaceutical companies since the early 1990s without successfully delivering an anti-obesity product to the market. More recently pharmaceutical companies have developed selective β3-AR agonists targeted at urinary inconsistencies and in 2012 Mirabegron (trade name Myrbetriq and Betmiga) was the first β3-AR agonist to be approved in the United States and Europe for the treatment of overactive bladder (OAB) syndrome.ment of overactive bladder (OAB) syndrome.
|
| rdfs:label |
Beta3-adrenergic agonist
|
